CITIUS ONCOLOGY INC (CTOR) Stock Price, Forecast & Analysis
NASDAQ:CTOR • US17331Y1091
CTOR Key Statistics, Chart & Performance
The current stock price of CTOR is 1.21 USD. In the past month the price increased by 5.22%. In the past year, price increased by 3.42%.
CTOR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CTOR. When comparing the yearly performance of all stocks, CTOR turns out to be only a medium performer in the overall market: it outperformed 51.38% of all stocks.
CTOR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CTOR. CTOR may be in some trouble as it scores bad on both profitability and health.
CTOR Financial Highlights
Over the last trailing twelve months CTOR reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS decreased by -8.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.53% | ||
| ROE | -55.19% | ||
| Debt/Equity | 0.08 |
CTOR Forecast & Estimates
7 analysts have analysed CTOR and the average price target is 6.12 USD. This implies a price increase of 405.79% is expected in the next year compared to the current price of 1.21.
CTOR Ownership
CTOR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 404.235B | ||
| AMGN | AMGEN INC | 16.66 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.63 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTOR
Company Profile
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Company Info
CITIUS ONCOLOGY INC
11 Commerce Drive, 1St Floor
Cranford NEW JERSEY US
Employees: 0
Phone: 19089676677
CITIUS ONCOLOGY INC / CTOR FAQ
What does CITIUS ONCOLOGY INC do?
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
What is the stock price of CITIUS ONCOLOGY INC today?
The current stock price of CTOR is 1.21 USD. The price increased by 3.42% in the last trading session.
Does CITIUS ONCOLOGY INC pay dividends?
CTOR does not pay a dividend.
What is the ChartMill rating of CITIUS ONCOLOGY INC stock?
CTOR has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is CITIUS ONCOLOGY INC (CTOR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTOR.
When does CITIUS ONCOLOGY INC (CTOR) report earnings?
CITIUS ONCOLOGY INC (CTOR) will report earnings on 2026-05-12.
What is the outstanding short interest for CITIUS ONCOLOGY INC?
The outstanding short interest for CITIUS ONCOLOGY INC (CTOR) is 6.25% of its float.